Identification

Name
Chlorphenamine
Accession Number
DB01114  (APRD00001, DB09440)
Type
Small Molecule
Groups
Approved
Description

A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. [PubChem]

Structure
Thumb
Synonyms
  • 1-(p-chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
  • 1-(p-chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine
  • 2-[p-chloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine
  • 3-(p-chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine
  • Chlorophenylpyridamine
  • Chlorphenamin
  • Chlorphenaminum
  • Chlorpheniramine
  • Chlorpheniramine polistirex
  • Chlorpheniraminum
  • Clorfenamina
  • Clorfeniramina
  • γ-(4-chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine
  • γ-(4-chlorophenyl)-γ-(2-pyridyl)propyldimethylamine
Product Ingredients
IngredientUNIICASInChI Key
Chlorpheniramine gluconate79YPK3BAIT25387-68-2OCMSTKFGYJZBIY-IFWQJVLJSA-N
Chlorpheniramine hydrochloride5S6VUP419V56343-98-7NOXNCSQBTYNMHD-UHFFFAOYSA-N
Chlorpheniramine maleateV1Q0O9OJ9Z113-92-8DBAKFASWICGISY-BTJKTKAUSA-N
Chlorpheniramine tannate72JT935YTT1405-56-7KOOFUFFGNZKXFG-HBNMXAOGSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlorpheniramine Maleate Injection USPLiquid10 mgIntramuscular; Intravenous; SubcutaneousOmega Laboratories LtdNot applicableNot applicableCanada
Chlortripolon Inj 10mg/mlLiquid10 mgIntramuscular; Intravenous; SubcutaneousSchering Plough1953-12-311999-08-04Canada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
4 Hour Allergy ReliefTablet4 mg/1OralBetter Living Brands1992-12-19Not applicableUs
Aller-chlorTablet4 mg/1OralLake Erie Medical Dba Quality Care Produts Llc1992-12-19Not applicableUs
Aller-chlorTablet4 mg/1OralA S Medication Solutions1992-12-192017-06-20Us
Aller-chlorSyrup2 mg/5mLOralRugby2014-03-20Not applicableUs
Aller-chlorTablet4 mg/1OralRugby1992-12-19Not applicableUs
Aller-ChlorSyrup2 mg/5mLOralRugby2003-01-17Not applicableUs
AllergyTablet4 mg/1OralAidarex Pharmaceuticals LLC1992-12-19Not applicableUs
AllergyTablet4 mg/1OralSupervalu1992-12-19Not applicableUs
AllergyTablet4 mg/1OralCardinal Health1992-12-19Not applicableUs
AllergyTablet4 mg/1OralAllegiant Health2014-12-15Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlorpheniramine MaleateTablet4 mg/1OralCardinal Health2011-06-06Not applicableUs
International/Other Brands
Chlo-Amine / Chlor-Trimeton (Schering-Plough) / Clofeniramina / Haynon / Piriton (GlaxoSmithKline)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
999 Cold RemedyChlorpheniramine maleate (2 mg/6000mg) + Acetaminophen (100 mg/6000mg)CapsuleOralChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd.2003-07-03Not applicableUs
999 Cold Remedy GranularChlorpheniramine maleate (4 mg/90g) + Acetaminophen (200 mg/90g)GranuleOralChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd.2003-07-03Not applicableUs
999 Ganmaoling ColdChlorpheniramine maleate (2 mg/1) + Acetaminophen (100 mg/1) + Caffeine (2 mg/1)CapsuleOralKingsway2012-07-30Not applicableUs
Acetaminophen, Chlorpheniramine Maleate, Dextromethorphan Hydrobromide, Phenylephrine HydrochlorideChlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Tablet, coatedOralAAA Pharmaceutical, Inc.2012-12-28Not applicableUs
Acetaminophen, Chlorpheniramine Maleate, Dextromethorphan Hydrobromide, Phenylephrine HydrochlorideChlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)Tablet, coatedOralAAA Pharmaceutical, Inc.2012-12-28Not applicableUs
Acetaminophen, Chlorpheniramine Maleate, Phenylephrine HydrochlorideChlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Phenylephrine hydrochloride (5 mg/1)Tablet, coatedOralAAA Pharmaceutical, Inc.2012-12-28Not applicableUs
Acetaminophen, Chlorpheniramine Maleate, Phenylephrine HydrochlorideChlorpheniramine maleate (2 mg/1) + Acetaminophen (325 mg/1) + Phenylephrine hydrochloride (5 mg/1)Tablet, coatedOralAAA Pharmaceutical, Inc.2012-12-28Not applicableUs
Acti PEChlorpheniramine maleate (4 mg/1) + Phenylephrine hydrochloride (10 mg/1)TabletOralP & L Development, LLC2015-02-28Not applicableUs
Actifed PEChlorpheniramine maleate (4 mg) + Phenylephrine hydrochloride (10 mg)TabletOralMcneil Consumer Healthcare Division Of Johnson & Johnson IncNot applicableNot applicableCanada
Actifed PE PlusChlorpheniramine maleate (2 mg) + Acetaminophen (500 mg) + Phenylephrine hydrochloride (5 mg)TabletOralMcneil Consumer Healthcare Division Of Johnson & Johnson IncNot applicableNot applicableCanada
Categories
UNII
3U6IO1965U
CAS number
132-22-9
Weight
Average: 274.788
Monoisotopic: 274.123676325
Chemical Formula
C16H19ClN2
InChI Key
SOYKEARSMXGVTM-UHFFFAOYSA-N
InChI
InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
IUPAC Name
[3-(4-chlorophenyl)-3-(pyridin-2-yl)propyl]dimethylamine
SMILES
CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1

Pharmacology

Indication

For the treatment of rhinitis, urticaria, allergy, common cold, asthma and hay fever.

Structured Indications
Pharmacodynamics

In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Chlorpheniramine, is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.

Mechanism of action

Chlorpheniramine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
USodium-dependent serotonin transporter
inhibitor
Human
USodium-dependent noradrenaline transporter
inhibitor
Human
USodium-dependent dopamine transporter
inhibitor
Human
Absorption

Well absorbed in the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding

72%

Metabolism

Primarily hepatic via Cytochrome P450 (CYP450) enzymes.

Route of elimination
Not Available
Half life

21-27 hours

Clearance
Not Available
Toxicity

Oral LD50 (rat): 306 mg/kg; Oral LD50 (mice): 130 mg/kg; Oral LD50 (guinea pig): 198 mg/kg [Registry of Toxic Effects of Chemical Substances. Ed. D. Sweet, US Dept. of Health & Human Services: Cincinatti, 2010.] Also a mild reproductive toxin to women of childbearing age.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Chlorphenamine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Chlorphenamine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Chlorphenamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Chlorphenamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Chlorphenamine.Experimental
AbirateroneThe serum concentration of Chlorphenamine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Chlorphenamine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Chlorphenamine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Chlorphenamine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Chlorphenamine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Chlorphenamine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorphenamine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Chlorphenamine.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Chlorphenamine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Chlorphenamine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorphenamine.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Chlorphenamine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Chlorphenamine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Chlorphenamine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Chlorphenamine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Chlorphenamine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Chlorphenamine.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Chlorphenamine.Approved, Illicit
AprepitantThe serum concentration of Chlorphenamine can be increased when it is combined with Aprepitant.Approved, Investigational
ArtemetherThe metabolism of Chlorphenamine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Chlorphenamine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Chlorphenamine.Approved
AtazanavirThe metabolism of Chlorphenamine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Chlorphenamine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Chlorphenamine.Vet Approved
AzelastineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Chlorphenamine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Chlorphenamine.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Chlorphenamine.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Chlorphenamine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Chlorphenamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Chlorphenamine.Approved
Benzylpenicilloyl PolylysineChlorphenamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Chlorphenamine.Approved
BetaxololThe metabolism of Chlorphenamine can be decreased when combined with Betaxolol.Approved
BoceprevirThe metabolism of Chlorphenamine can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Chlorphenamine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Chlorphenamine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorphenamine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Chlorphenamine.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Chlorphenamine.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Chlorphenamine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Chlorphenamine.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorphenamine.Approved, Investigational
BuprenorphineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Chlorphenamine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorphenamine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorphenamine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Chlorphenamine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Chlorphenamine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Chlorphenamine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Chlorphenamine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorphenamine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Chlorphenamine.Investigational
CarbamazepineThe metabolism of Chlorphenamine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Chlorphenamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Chlorphenamine.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Chlorphenamine.Approved
CelecoxibThe metabolism of Chlorphenamine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Chlorphenamine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Chlorphenamine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Chlorphenamine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorphenamine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Chlorphenamine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chlorphenamine.Approved
ChloroquineThe metabolism of Chlorphenamine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Chlorphenamine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Chlorphenamine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Chlorphenamine.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Chlorphenamine.Approved
CholecalciferolThe metabolism of Chlorphenamine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Chlorphenamine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Chlorphenamine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chlorphenamine.Approved, Vet Approved
CitalopramThe metabolism of Chlorphenamine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Chlorphenamine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Chlorphenamine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Chlorphenamine.Approved
ClobazamThe metabolism of Chlorphenamine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Chlorphenamine.Investigational
ClomipramineThe metabolism of Chlorphenamine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Chlorphenamine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Chlorphenamine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Chlorphenamine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorphenamine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Chlorphenamine.Experimental
ClotrimazoleThe metabolism of Chlorphenamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Chlorphenamine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Chlorphenamine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Chlorphenamine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorphenamine.Approved, Illicit
ConivaptanThe serum concentration of Chlorphenamine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Chlorphenamine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorphenamine.Approved
CyclosporineThe metabolism of Chlorphenamine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Chlorphenamine.Approved
DabrafenibThe serum concentration of Chlorphenamine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorphenamine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Chlorphenamine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Chlorphenamine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Chlorphenamine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Chlorphenamine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Chlorphenamine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Chlorphenamine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Chlorphenamine.Approved
DesipramineThe metabolism of Chlorphenamine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Chlorphenamine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Chlorphenamine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlorphenamine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorphenamine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Chlorphenamine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorphenamine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorphenamine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Chlorphenamine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Chlorphenamine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Chlorphenamine.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Chlorphenamine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorphenamine.Approved, Illicit
DihydroergotamineThe metabolism of Chlorphenamine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorphenamine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorphenamine.Experimental, Illicit
DiltiazemThe metabolism of Chlorphenamine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Chlorphenamine.Approved
DiphenhydramineThe metabolism of Chlorphenamine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorphenamine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Chlorphenamine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Chlorphenamine.Vet Approved
DosulepinThe metabolism of Chlorphenamine can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Doxepin.Approved
DoxycyclineThe metabolism of Chlorphenamine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Chlorphenamine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved, Illicit
DronedaroneThe metabolism of Chlorphenamine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Chlorphenamine.Experimental, Illicit
DuloxetineThe metabolism of Chlorphenamine can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorphenamine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Chlorphenamine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Chlorphenamine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Chlorphenamine.Approved, Investigational
EliglustatThe metabolism of Chlorphenamine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Chlorphenamine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Chlorphenamine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Chlorphenamine.Approved, Investigational
EnzalutamideThe serum concentration of Chlorphenamine can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Chlorphenamine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Chlorphenamine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorphenamine.Approved
EthanolChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorphenamine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlorphenamine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Chlorphenamine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Chlorphenamine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Chlorphenamine.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Chlorphenamine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorphenamine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Chlorphenamine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Chlorphenamine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Chlorphenamine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorphenamine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Chlorphenamine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Chlorphenamine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Chlorphenamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorphenamine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorphenamine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Chlorphenamine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Chlorphenamine.Experimental
FluconazoleThe metabolism of Chlorphenamine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Chlorphenamine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Chlorphenamine.Approved, Illicit
FluoxetineThe metabolism of Chlorphenamine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorphenamine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorphenamine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorphenamine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Chlorphenamine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Chlorphenamine.Approved
FluvoxamineThe metabolism of Chlorphenamine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Chlorphenamine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Chlorphenamine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Chlorphenamine.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Chlorphenamine.Approved, Illicit
Fusidic AcidThe serum concentration of Chlorphenamine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorphenamine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Chlorphenamine.Approved, Illicit
GepefrineGepefrine may decrease the sedative activities of Chlorphenamine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Chlorphenamine.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Chlorphenamine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Chlorphenamine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Chlorphenamine.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Chlorphenamine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorphenamine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Chlorphenamine.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Chlorphenamine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorphenamine.Approved, Investigational
HydrocodoneChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorphenamine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Chlorphenamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
IdelalisibThe serum concentration of Chlorphenamine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Iloperidone.Approved
ImatinibThe metabolism of Chlorphenamine can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Chlorphenamine can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Chlorphenamine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Chlorphenamine.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Chlorphenamine.Approved
IsavuconazoniumThe metabolism of Chlorphenamine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Chlorphenamine.Approved, Vet Approved
IsoniazidThe metabolism of Chlorphenamine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Chlorphenamine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Chlorphenamine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Chlorphenamine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorphenamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Chlorphenamine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorphenamine.Approved
KetoconazoleThe metabolism of Chlorphenamine can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlorphenamine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Chlorphenamine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorphenamine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorphenamine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Chlorphenamine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Chlorphenamine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Chlorphenamine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Chlorphenamine.Illicit
LopinavirThe metabolism of Chlorphenamine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Chlorphenamine.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Chlorphenamine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorphenamine.Approved
LorcaserinThe metabolism of Chlorphenamine can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Chlorphenamine.Approved
LovastatinThe metabolism of Chlorphenamine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorphenamine.Approved
LuliconazoleThe serum concentration of Chlorphenamine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Chlorphenamine can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Chlorphenamine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorphenamine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved, Vet Approved
ManidipineThe metabolism of Chlorphenamine can be decreased when combined with Manidipine.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Chlorphenamine.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Chlorphenamine.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Chlorphenamine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Chlorphenamine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Chlorphenamine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Chlorphenamine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Chlorphenamine.Approved
MephedroneMephedrone may decrease the sedative activities of Chlorphenamine.Investigational
MephentermineMephentermine may decrease the sedative activities of Chlorphenamine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorphenamine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorphenamine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Chlorphenamine.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorphenamine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Chlorphenamine.Approved
MethadoneThe metabolism of Chlorphenamine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Chlorphenamine.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Chlorphenamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Chlorphenamine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Chlorphenamine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Chlorphenamine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorphenamine.Approved
MethotrimeprazineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlorphenamine.Approved, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Chlorphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Chlorphenamine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chlorphenamine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Chlorphenamine.Approved, Investigational
MetyrosineChlorphenamine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlorphenamine.Approved, Illicit
Midomafetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Chlorphenamine.Experimental, Illicit
MidostaurinThe metabolism of Chlorphenamine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Chlorphenamine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved, Investigational
MirabegronThe metabolism of Chlorphenamine can be decreased when combined with Mirabegron.Approved
MirtazapineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Chlorphenamine can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may decrease the sedative activities of Chlorphenamine.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Chlorphenamine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorphenamine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorphenamine.Approved
NefazodoneThe metabolism of Chlorphenamine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Chlorphenamine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Chlorphenamine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Chlorphenamine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Chlorphenamine can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Chlorphenamine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Chlorphenamine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Chlorphenamine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Chlorphenamine.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Chlorphenamine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Chlorphenamine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorphenamine.Approved, Investigational
OlaparibThe metabolism of Chlorphenamine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Chlorphenamine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlorphenamine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Chlorphenamine.Approved, Illicit
OrphenadrineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Chlorphenamine.Investigational
OsimertinibThe serum concentration of Chlorphenamine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorphenamine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Chlorphenamine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Chlorphenamine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chlorphenamine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorphenamine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorphenamine.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Chlorphenamine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chlorphenamine.Approved
PanobinostatThe serum concentration of Chlorphenamine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Chlorphenamine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Chlorphenamine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Chlorphenamine.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorphenamine.Approved, Vet Approved
PentobarbitalThe metabolism of Chlorphenamine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Chlorphenamine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Chlorphenamine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorphenamine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorphenamine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Chlorphenamine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Chlorphenamine.Experimental
PhenobarbitalThe metabolism of Chlorphenamine can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Chlorphenamine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Chlorphenamine.Approved
PhenterminePhentermine may decrease the sedative activities of Chlorphenamine.Approved, Illicit
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Chlorphenamine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Chlorphenamine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Chlorphenamine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Chlorphenamine.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Chlorphenamine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleChlorphenamine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Chlorphenamine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Chlorphenamine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlorphenamine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Chlorphenamine.Approved
PrimidoneThe metabolism of Chlorphenamine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Chlorphenamine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorphenamine.Approved, Vet Approved
PromazineThe metabolism of Chlorphenamine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Chlorphenamine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Chlorphenamine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chlorphenamine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorphenamine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Chlorphenamine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorphenamine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Chlorphenamine.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Chlorphenamine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Chlorphenamine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Chlorphenamine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorphenamine.Approved
QuinidineThe metabolism of Chlorphenamine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Chlorphenamine can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Chlorphenamine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Chlorphenamine.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Chlorphenamine.Approved, Investigational
RanolazineThe metabolism of Chlorphenamine can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorphenamine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorphenamine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorphenamine.Approved
RifabutinThe metabolism of Chlorphenamine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Chlorphenamine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Chlorphenamine can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlorphenamine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Chlorphenamine.Investigational
RitobegronRitobegron may decrease the sedative activities of Chlorphenamine.Investigational
RitonavirThe metabolism of Chlorphenamine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Chlorphenamine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Chlorphenamine.Vet Approved
RopiniroleChlorphenamine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorphenamine.Approved
RotigotineChlorphenamine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorphenamine.Approved
SaquinavirThe metabolism of Chlorphenamine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorphenamine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Chlorphenamine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Chlorphenamine.Approved, Withdrawn
SertralineThe metabolism of Chlorphenamine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorphenamine.Approved, Vet Approved
SildenafilThe metabolism of Chlorphenamine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Chlorphenamine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Chlorphenamine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
St. John's WortThe serum concentration of Chlorphenamine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Chlorphenamine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorphenamine.Approved, Investigational
SulfisoxazoleThe metabolism of Chlorphenamine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlorphenamine.Approved
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Chlorphenamine.Experimental
SuvorexantChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Chlorphenamine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Chlorphenamine can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Chlorphenamine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorphenamine.Approved
TerbinafineThe metabolism of Chlorphenamine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Chlorphenamine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Chlorphenamine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Chlorphenamine.Investigational
ThalidomideChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlorphenamine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Chlorphenamine.Approved, Vet Approved
ThioridazineChlorphenamine may increase the arrhythmogenic activities of Thioridazine.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chlorphenamine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Chlorphenamine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Chlorphenamine.Approved, Investigational
TiclopidineThe metabolism of Chlorphenamine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Chlorphenamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Chlorphenamine.Experimental
TipranavirThe metabolism of Chlorphenamine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorphenamine.Approved
TocilizumabThe serum concentration of Chlorphenamine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorphenamine.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Chlorphenamine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorphenamine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Chlorphenamine.Experimental
TranylcypromineThe metabolism of Chlorphenamine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Chlorphenamine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlorphenamine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Chlorphenamine.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Chlorphenamine.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorphenamine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Chlorphenamine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorphenamine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlorphenamine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Chlorphenamine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Chlorphenamine.Approved, Investigational
VenlafaxineThe metabolism of Chlorphenamine can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Chlorphenamine.Experimental
VerapamilThe metabolism of Chlorphenamine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Chlorphenamine.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Chlorphenamine.Experimental
VoriconazoleThe metabolism of Chlorphenamine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Chlorphenamine.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Chlorphenamine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Chlorphenamine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorphenamine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Chlorphenamine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Chlorphenamine.Vet Approved
ZolpidemChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Chlorphenamine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Chlorphenamine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Chlorphenamine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorphenamine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.

References

Synthesis Reference

Anil M. Salpekar, John Johnson, "Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom." U.S. Patent US4631284, issued April, 1975.

US4631284
General References
  1. MSDS [Link]
External Links
Human Metabolome Database
HMDB01944
KEGG Drug
D07398
KEGG Compound
C06905
PubChem Compound
2725
PubChem Substance
46508253
ChemSpider
2624
BindingDB
35938
ChEBI
52010
ChEMBL
CHEMBL505
Therapeutic Targets Database
DAP000336
PharmGKB
PA448960
IUPHAR
1213
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Chlorpheniramine
ATC Codes
R06AB54 — Chlorphenamine, combinationsR06AB04 — Chlorphenamine
AHFS Codes
  • 04:04.20
PDB Entries
Not Available
FDA label
Not Available
MSDS
Download (72.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers4
2CompletedTreatmentAllergic Reactions1
2TerminatedTreatmentAllergic Rhinitis (AR)1
2Unknown StatusTreatmentRhinitis, Seasonal, Allergic1
3Not Yet RecruitingTreatmentFlu Symptoms1
3Unknown StatusTreatmentAcute Rhinitis / Flu-like Syndromes1
3WithdrawnTreatmentAcute Rhinitis1
4Unknown StatusTreatmentVitiligo1
Not AvailableCompletedBasic ScienceHypovolaemia / Temperature Change, Body1
Not AvailableUnknown StatusPreventionPoisoning1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
GranuleOral
Capsule, liquid filledOral
Tablet, effervescentOral
Granule, effervescentOral
Powder, for solutionOral
SyrupOral2 mg/5mL
Liquid; tabletIntramuscular; Oral; Subcutaneous
Liquid; tabletOral; Parenteral
Granule, for solutionOral
LiquidTopical
Tablet, chewableOral
LiquidOral
SolutionOral
Tablet, extended releaseOral12 mg/1
Tablet, extended releaseOral12 mg
Kit; tablet; tablet, extended releaseOral
TabletOral12 mg
Tablet, film coated, extended releaseOral12 mg/1
LiquidIntramuscular; Intravenous; Subcutaneous10 mg
SyrupOral2.5 mg
Kit; tabletOral
KitOral
Kit
Tablet, extended releaseOral
Tablet, sugar coatedOral
LozengeOral2 mg/1
Kit; powder, for solutionOral
LiquidOral2 mL/mL
LiquidOral2 mg/5mL
Tablet, coatedOral4 mg/1
Kit; powderOral
TabletOral4 mg/1
SuspensionOral
Tablet, film coatedOral
CapsuleOral1.25 mg/1
Suspension, extended releaseOral
Capsule, delayed release pelletsOral
CapsuleOral
Tablet, multilayerOral
TabletOral4 mg
PowderOral
Capsule, gelatin coatedOral
TabletOral
Tablet, coatedOral
SyrupOral
Capsule, extended releaseOral
Prices
Unit descriptionCostUnit
Ahist 12 mg tablet1.1USD tablet
Myci chlor-tan 8 mg caplet0.75USD caplet
Chlorpheniramine powder0.67USD g
Chlor-trimeton allergy0.31USD each
Chlor-trimeton 8 mg repetab0.24USD tablet
Aller-chlor 4 mg tablet0.06USD tablet
Pediacare allergy solution0.05USD ml
Allergy 4 mg tablet0.04USD tablet
Chlorpheniramine 4 mg tablet0.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7863287No2007-02-282027-02-28Us
US8062667No2009-03-292029-03-29Us
US8790700No2007-03-152027-03-15Us
US9066942No2012-01-032032-01-03Us
US6383471No1999-04-062019-04-06Us
US6248363No1999-11-232019-11-23Us
US9107921No2012-01-032032-01-03Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
boiling point (°C)142 °CNot Available
water solubility5500 mg/L (at 37 °C)BEILSTEIN
logP3.38HANSCH,C ET AL. (1995)
pKa9.13 (at 25 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility0.0519 mg/mLALOGPS
logP3.74ALOGPS
logP3.58ChemAxon
logS-3.7ALOGPS
pKa (Strongest Basic)9.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area16.13 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity80.85 m3·mol-1ChemAxon
Polarizability30.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9754
Blood Brain Barrier+0.962
Caco-2 permeable+0.8749
P-glycoprotein substrateSubstrate0.6136
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.9376
Renal organic cation transporterInhibitor0.7916
CYP450 2C9 substrateNon-substrate0.8026
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6472
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9096
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9023
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7501
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9183
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.3361 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8702
hERG inhibition (predictor II)Inhibitor0.7145
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0zfr-6290000000-2ca3230cde716588805e
Mass Spectrum (Electron Ionization)MSsplash10-0zfr-6490000000-8e58cd1c686f23a7dac6
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-01b9-3900000000-ea4ccfd2afe05f49fc7a
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-004i-0090000000-9e46eb080de95d4f8f8e
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-014i-1920000000-d2d2acf559d9070a1d47
MS/MS Spectrum - EI-B (Unknown) , PositiveLC-MS/MSsplash10-0zfr-6190000000-2ca3230cde716588805e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0290000000-03651b7b90a1745fdf23
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0uy0-0960000000-1f750af75fe542c6c06f
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pheniramines
Direct Parent
Pheniramines
Alternative Parents
Chlorobenzenes / Aralkylamines / Aryl chlorides / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
Pheniramine / Chlorobenzene / Halobenzene / Aralkylamine / Aryl chloride / Benzenoid / Monocyclic benzene moiety / Aryl halide / Heteroaromatic compound / Tertiary aliphatic amine
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
tertiary amino compound, pyridines, monochlorobenzenes (CHEBI:52010)

Targets

Details
1. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Tagawa M, Kano M, Okamura N, Higuchi M, Matsuda M, Mizuki Y, Arai H, Iwata R, Fujii T, Komemushi S, Ido T, Itoh M, Sasaki H, Watanabe T, Yanai K: Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. Br J Clin Pharmacol. 2001 Nov;52(5):501-9. [PubMed:11736858]
  3. Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF 3rd, Guinosso PJ Jr, Lynch JJ Jr: Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res. 1995 Jan;76(1):110-9. [PubMed:8001268]
  4. Hasenohrl RU, Kuhlen A, Frisch C, Galosi R, Brandao ML, Huston JP: Comparison of intra-accumbens injection of histamine with histamine H1-receptor antagonist chlorpheniramine in effects on reinforcement and memory parameters. Behav Brain Res. 2001 Oct 15;124(2):203-11. [PubMed:11640974]
  5. Yasuda SU, Wellstein A, Likhari P, Barbey JT, Woosley RL: Chlorpheniramine plasma concentration and histamine H1-receptor occupancy. Clin Pharmacol Ther. 1995 Aug;58(2):210-20. [PubMed:7648771]
  6. Nicholson AN, Pascoe PA, Turner C, Ganellin CR, Greengrass PM, Casy AF, Mercer AD: Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol. 1991 Sep;104(1):270-6. [PubMed:1686208]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J: In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos. 1998 Jun;26(6):536-9. [PubMed:9616188]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:53